

Attorney Docket No.: ISPH-0501  
Inventors: Baker et al.  
Serial No.: 09/824,322  
Filing Date: April 2, 2001  
Page 2

effective amount of an oligonucleotide up to 30 nucleotides in length complementary to a nucleic acid molecule encoding human tumor necrosis factor- $\alpha$  (SEQ ID NO:1).

Please cancel claim 2.

**REMARKS**

This preliminary amendment is being made in response to a telephone interview with Examiner Schultz on April 9, 2002. Claim 2 has been canceled. Claim 1 has been amended to incorporate the SEQ ID NO. of the target sequence. This amendment to the claim is based on teachings throughout the specification as filed. No new matter has been added by this amendment.

Attached hereto is a marked up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Respectfully submitted,

*Jane Massey Licata*

Jane Massey Licata  
Registration No. 32,257

Date: April 10, 2002  
Licata & Tyrrell P.C.  
66 Main Street  
Marlton, N.J. 08053  
856-810-1515

Attorney Docket No.: ISPH-0501  
Inventors: Baker et al.  
Serial No.: 09/824,322  
Filing Date: April 2, 2001  
Page 3

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

Claim 2 has been canceled.

Claim 1 has been amended as follows:

1. (Amended) A method of treating an inflammatory disorder in an individual comprising administering to said individual an effective amount of an oligonucleotide up to 30 nucleotides in length complementary to a nucleic acid molecule encoding human tumor necrosis factor- $\alpha$  (SEQ ID NO:1).